SciELO - Scientific Electronic Library Online

 
vol.34 issue2Cerebral Venous Thrombosis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Archivos de Medicina Interna

Print version ISSN 0250-3816On-line version ISSN 1688-423X

Abstract

PINEIRO, Dra. Natalia; CORREA, Fernando  and  RAMAGLI, Alicia. Treating Rheumatoid Arthritis with Anti-TNF. : Experience in Uruguay. Arch. Med Int [online]. 2012, vol.34, n.2, pp.38-42. ISSN 0250-3816.

Abstract: Arch Med Interna 2012 - 34(2): 38-41 Rheumatoid Arthritis (RA) is a systemic autoimmune disease, associated to an impairment of quality of life and increased morbimortality. Remissive therapies of RA include therapies with Disease Modifying Anti Rheumatic Drugs (DMARDs) and Biologic Agents. Therapy with the Anti-Tumor Necrosis Factor (Anti-TNF) was incorporated to the drugs reimbursed by the National Resource Fund (FNR) in March 2010. The study assessed a cohort of patients that started therapy before May 1 2011. Objectives: to characterize the population and to evaluate the efficacy outcomes of therapy, based on the evolution of DAS 28 scores. Results: 69 patients were enrolled. The mean pre and post therapy DAS 28 scores showed improvement (p < 0.05). Improvement criteria in 76.4% (low grade activity 37.3% and remission 14.9%). Adverse effects in 20 patients (in 3 cases it led to discontinuation of therapy). Drug changes, primary cause: treatment failure (8/9). Conclusions: Over 70% achieve improvement criteria; hence, although the results in this first evaluation of the response may be classified as good, they need to be monitored with time.

Keywords : Keywords: Rheumatoid arthritis, AntiTNF, DAS28, Adalimumab, Etanercept, Infliximab..

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License